[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

AFTER-HOURS TRADING - Breaking News...%CUSTOM_MINE



AFTER-HOURS TRADING - BREAKING NEWS

Get Quote - http://quote.money.cnn.com/quote/quote?symbols=htds

Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tubercin
Toxicity Study and Formation of Scientific Advisory Panel - Wednesday December
3, 8:04 pm ET

DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases
Incorporated (Pink Sheets: HTDS) announces today that the spokesperson for the
independent medical group conducting the testing for HTTD (HTDS) has forwarded
the formal Testing Results of Tubercin®'s Toxicity Trials to HTTD.

Tubercin of five different concentrations was administered to five groups of
mice. A pathologist at the University of Oklahoma Health Science Center
performed autopsies. The mice were randomized and only the control mouse was
known to the pathologist, as stated in the cover letter of the Pathology
Report.

The report concludes, "All tissues evaluated, visceral organs and the brain
were essentially normal in appearance." "The importance of this report is even
better than I expected," stated the spokesperson for the medical group. "As
the testing continues and if the results are similar to those of Chemotherapy
and or radiation with no harmful side effects, Tubercin has enormous potential
for the treatment of cancer and the immune system."

The President and CEO of HTTD, Mr. Colm J. King is in the process of forming a
Scientific Advisory Panel with leading Oncologists and Immunologists from
prestigious institutions in the U.S. The panel will review the reports and
results of Tubercin®'s findings and will report back to Mr. King with the
ongoing reports in layman language for the shareholders.

"We are continuing to receive promising results regarding Tubercin® and we're
looking forward to additional positive results in the near future," stated Mr.
King. "These tests prove that Tubercin® is non-toxic and is the first step on
the way to human clinical trials as well as the first positive breakthrough
conducted in the United States with an independent medical group for
Tubercin®.

Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated
("HTTD") holds the international marketing rights, except South Korea, to
Tubercin®, a patented immunostimulant developed for combating Cancer under
medical patent (US Patent 6,274,356). The unique properties unlike other
cancer products are clearly stated in the abstract summary of the patent... "A
carbohydrate complex, which is a mixture of low molecular-weight
polysaccharides of an arabinomannan structure extracted from Mycobacterium
tuberculosis, is highly effective in treating various cancer patients without
incurring any adverse side effects."






Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Those statements include statements regarding the intent, belief
or current expectations of the Company and its management. Such statements
reflect management's current views, are based on certain assumptions and
involve risks and uncertainties. Actual results, events, or performance may
differ materially from the above forward-looking statements due to a number of
important factors, and will be dependent upon a variety of factors, including,
but not limited to, our ability to obtain additional financing and access
funds from our existing financing arrangements that will allow us to continue
our current and future operations and whether demand for our product and
testing service in domestic and international markets will continue to expand.
The Company undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the date hereof
or to reflect any change in the Company's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.



























yxrbll ztbbiodc oct z gdhbq rvkulmfwtrqzjc
ikuaf
vcjqqozydp
dessjc  udqimi